Enhabit Posts Mixed Q4 Results Amid Pending Acquisition
ENHABIT INC (NYSE:EHAB) reported financial results for the fourth quarter of 2025, delivering a performance that narrowly missed analyst revenue expectations while surpassing adjusted earnings estimates. The report comes against the backdrop of a recently announced definitive agreement to be acquired by private equity firm Kinderhook Industries.
Earnings and Revenue Versus Estimates
The home health and hospice provider reported quarterly net service revenue of $270.4 million. This figure fell short of the analyst consensus estimate of approximately $276.0 million. On the profitability front, the company posted an adjusted diluted earnings per share (EPS) of $0.14, which exceeded the analyst estimate of $0.1445.
The bottom-line beat was supported by improved operational efficiency and cost management. Key financial highlights from the quarter include:
- Consolidated Adjusted EBITDA: Increased 11.6% year-over-year to $28.0 million.
- Adjusted EBITDA Margin: Expanded to 10.4%, up from 9.7% in the prior-year period.
- Reported Net Loss: The company reported a GAAP net loss of $38.7 million, or $0.76 per diluted share, primarily due to a $44.7 million non-cash impairment of goodwill charge.
Market Reaction and Context
Following the earnings release, the stock's after-market performance showed little immediate movement. However, the security has seen significant appreciation over the past month, rising approximately 25.8%. This longer-term price action is almost entirely attributable to the pending acquisition announcement on February 23, 2026, not the quarterly earnings performance.
Kinderhook Industries has agreed to acquire Enhabit for $13.80 per share in cash, a deal valued at approximately $1.1 billion. Given this pending transaction, which is expected to close in the second quarter of 2026, Enhabit has suspended its practice of providing financial guidance. This lack of forward-looking commentary from management is a direct result of the merger process and is neither a positive nor negative signal regarding the underlying business.
Operational Highlights and Segment Performance
Beyond the headline financials, the fourth quarter demonstrated continued operational progress in what CEO Barb Jacobsmeyer termed an "emerging growth story."
- Home Health Segment: Revenue grew 3.2% year-over-year to $206.8 million. A standout was non-Medicare admissions growth of 16.0%, helping to offset a 4.0% decline in Medicare average daily census. The segment also achieved a 3.5% reduction in cost per patient day.
- Hospice Segment: This was the faster-growing division, with revenue increasing 10.0% to $63.6 million. Hospice average daily census grew 9.9% year-over-year, marking sequential growth every quarter since Q1 2024.
- Balance Sheet Strength: The company continued its debt reduction strategy, prepaying $15.0 million in bank debt during the quarter. This marks the eighth consecutive quarter of debt prepayment, resulting in a leverage ratio of 3.7x.
Looking Ahead
With the merger agreement in place, the investment narrative for Enhabit has shifted from evaluating its standalone growth prospects to assessing the likelihood of the deal's completion at the agreed-upon price. The company will not host a conference call related to these earnings.
For investors tracking the company's fundamental performance prior to the acquisition, detailed historical earnings data and future analyst estimates for revenue and EPS can be viewed on the Enhabit earnings page.
Disclaimer: This article is for informational purposes only and does not constitute financial advice, investment recommendation, or an offer to buy or sell any security. Investors should conduct their own research and consult with a qualified financial advisor before making any investment decisions.
